STOCK TITAN

Atara Biotherape - ATRA STOCK NEWS

Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.

Overview of Atara Biotherapeutapeutics Inc

Atara Biotherapeutics Inc (Symbol: ATRA) is a U.S.-based biotherapeutics company dedicated to developing innovative therapies aimed at transforming the treatment landscape for patients suffering from serious diseases. With a strong focus on immunotherapy, cellular therapy, and transformative therapeutic solutions, Atara Biotherapeutics leverages cutting‐edge research into activin, myostatin and other critical growth factors to address complex underlying mechanisms of diseases such as solid tumors, hematologic cancers, and autoimmune disorders.

Core Business and Operational Focus

Atara Biotherapeutics operates in the competitive U.S. healthcare sector with a single, integrated operating segment that is focused entirely on therapeutic development. The company drives its research and development efforts by exploring the intersection of cellular therapies and T-cell engineering. This strategy underscores its commitment to harnessing the body’s own defense mechanisms to create targeted, potent treatments that aim to disrupt disease progression. The company’s approach is built on over a decade of research and clinical exploration, resulting in a pipeline of innovative product candidates that seek to redefine current therapeutic standards.

Innovative Product Candidates and Research Direction

The company has developed multiple innovative product candidates designed to address critical disease pathways. Its portfolio includes T-cell based therapies and advanced platforms such as the CAR T Platform, which highlights the company’s specialization in cellular therapy. In addition to its internally developed candidates, Atara Biotherapeutics has also engaged in strategic collaborations that bolster its research capacity and clinical insights. These collaborations enable the sharing of specialized expertise and resources, further fortifying its development of safe and effective therapeutic solutions.

Scientific Approach and Industry Collaboration

Atara Biotherapeutics’ research is inspired by pioneering discoveries in growth factor biology, which inform its approach to reversing or halting pathological processes underlying various diseases. The company’s commitment to scientific rigor is reflected in its methodical evaluation of molecular targets, including activin and myostatin, that have significant implications for patient care. Collaborations with renowned institutions, such as partnerships with leading cancer centers, play a vital role in validating and accelerating the development of its therapeutic candidates. This synergistic approach fosters an environment of innovation and precision medicine.

Market Position and Competitive Landscape

Positioned within the biotech and healthcare sectors, Atara Biotherapeutics faces both significant opportunities and challenges characteristic of drug development companies. Its niche focus on T-cell and cellular therapies places it among a competitive group of innovators striving to address critical unmet medical needs. What sets Atara apart is the integration of robust scientific research with strategic collaborations and a focused therapeutic pipeline. By concentrating on areas where traditional treatments have reached their limits, the company reinforces its commitment to offering alternative, mechanism-driven therapeutic options that are supported by extensive preclinical and clinical research.

Expertise and Trustworthiness in Therapeutic Development

The depth of experience at Atara Biotherapeutics is demonstrated through its comprehensive approach to treatment development. The company applies advanced scientific methods and leverages ongoing research to refine its product candidates continuously. Its clinical development strategies emphasize safety, efficacy, and reliable delivery of therapeutic benefits to patients. This dedication to scientific excellence, combined with collaborations with esteemed medical institutions, enhances its credibility and positions the company as a knowledgeable entity within the biotherapeutics space.

Key Business Segments and Value Proposition

While the company's operations are centralized within a single reportable segment, its focus encompasses the entire spectrum of therapeutic innovation—from early-stage research to clinical development. This unified operational focus allows Atara Biotherapeutics to efficiently coordinate its research, streamline development processes, and pivot when necessary based on scientific insights. The primary value proposition of the company lies in its ability to translate complex biological insights into practical therapies, thereby offering new hope and treatment avenues for patients facing severe and often life-threatening conditions.

Conclusion

Atara Biotherapeutics Inc presents a comprehensive example of modern biotherapeutic innovation. By maintaining a steadfast focus on cellular and T-cell therapies along with robust scientific and clinical collaborations, the company is systematically addressing some of the most challenging areas in healthcare. Its endeavors are underpinned by scientific expertise, rigorous methodology, and a commitment to developing therapies that are both transformative and rooted in deep molecular insights, reaffirming its position as a significant research-driven entity in the biotherapeutics industry.

Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) announced advancements in its T-cell immunotherapy research at the TCT 2021 meeting, including data on its lead candidate, tab-cel®.

Key points include consistent therapeutic activity across tab-cel® production, clinical studies in EBV-related diseases, and the advancement of ATA3219, a next-generation CAR T therapy. Further, a novel testing solution for non-engineered therapies, developed with CareDx, aims to enhance therapeutic monitoring.

The company remains on track for a Biologics License Application in Q3 2021, based on promising interim trial data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) has announced six poster presentations at the upcoming Transplantation & Cellular Therapy (TCT) Meeting, occurring virtually from February 8-12, 2021. The presentations will focus on Atara's innovative allogeneic EBV T-cell platform, highlighting the mechanism of action of tabelecleucel (tab-cel®) and an assay for non-engineered T-cell therapies. Key posters include studies on tabelecleucel's clinical efficacy and the development of a new CAR-T therapy, ATA3219, without gene editing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.94%
Tags
conferences
-
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) revealed its strategic priorities and progress at the upcoming J.P. Morgan Healthcare Conference on January 13, 2021. CEO Pascal Touchon emphasized significant advancements in 2020, particularly for its lead candidate tab-cel® for EBV-positive post-transplant lymphoproliferative disease. Key milestones include the completion of the BLA rolling submission and anticipated approvals in the U.S. and EU in 2022. Additionally, Atara plans to provide updates on ATA188 for progressive MS and CAR T programs throughout the year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
none
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) announced that CEO Pascal Touchon will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13 at 1:30 PM PST/4:30 PM EST. This event will showcase Atara's advancements in T-cell immunotherapy, particularly its allogeneic EBV T-cell platform aimed at treating serious diseases like solid tumors and autoimmune disorders. A live audio webcast will be available on atarabio.com, with a recorded version accessible for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) has not yet initiated the Biologics License Application (BLA) for tab-cel® (tabelecleucel), under Phase 3 development for EBV-positive post-transplant lymphoproliferative disease. The Company awaits a procedural decision from the FDA regarding historical data presentation in the BLA. Despite the delay, Atara remains on track to complete the BLA filing in Q3 2021, with an objective response rate of 50% reported in the pivotal study. Ongoing discussions with the FDA are described as constructive.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
Rhea-AI Summary

Atara Biotherapeutics, Inc. (Nasdaq: ATRA) announced a public offering of 5,102,041 shares at $24.50 each and pre-funded warrants for 2,040,816 shares at $24.4999, totaling approximately $175 million in gross proceeds. The offering is set to close on December 11, 2020, pending customary conditions. Citigroup, Evercore ISI, and Mizuho Securities serve as joint book-running managers, with an option for underwriters to purchase an additional 1,071,428 shares. The offering is conducted under a previously filed registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.57%
Tags
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) has initiated a public offering of $150 million in common stock, with a potential additional $22.5 million from underwriters. The offering is subject to market conditions, and there are no guarantees regarding its completion or terms. The shares will be sold by Atara Biotherapeutics, leveraging a previously filed shelf registration statement with the SEC. Citigroup, Evercore ISI, and Mizuho Securities are acting as joint book-running managers for this offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
-
Rhea-AI Summary

Atara Biotherapeutics (Nasdaq: ATRA) announced the first preclinical evaluation of ATA3219, a novel off-the-shelf CAR T-cell therapy targeting CD19, and data from its Phase II study of tab-cel® for EBV-driven diseases. The results showcased ATA3219's potent antitumor activity and safety in preclinical models. Atara plans to submit an IND for ATA3219 in 2021 following a successful FDA meeting. Additionally, tab-cel® demonstrated high response rates in patients with life-threatening EBV viremia, with an overall survival rate of 100% at one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
-
Rhea-AI Summary

Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) have entered a global license agreement for mesothelin-directed CAR T-cell therapies targeting solid tumors. This collaboration involves the development candidate ATA3271 and an autologous version, ATA2271. Atara will oversee IND-enabling studies while Bayer manages the IND submission and clinical development. Atara receives an upfront payment of $60 million and can earn up to $610 million in milestones plus royalties on net sales. This partnership aims to enhance the development of off-the-shelf CAR T-cell therapies for challenging cancer types.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
Rhea-AI Summary

Atara Biotherapeutics, a leader in T-cell immunotherapy, has announced participation in two upcoming virtual conferences. The Stifel 2020 Virtual Healthcare Conference is set for November 18, 2020, featuring a fireside chat with CEO Pascal Touchon. The Evercore ISI 3rd Annual Virtual HealthCONx Conference will take place on December 2, 2020, with chats including Pascal Touchon and Jakob Dupont, Global Head of Research and Development. Both events will be accessible via live webcasts on the company's website, with archived replays available for 14 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
conferences

FAQ

What is the current stock price of Atara Biotherape (ATRA)?

The current stock price of Atara Biotherape (ATRA) is $5.59 as of April 4, 2025.

What is the market cap of Atara Biotherape (ATRA)?

The market cap of Atara Biotherape (ATRA) is approximately 34.8M.

What is the core focus of Atara Biotherapeutics?

Atara Biotherapeutics focuses on the development of innovative cellular therapies and immunotherapies designed to treat serious diseases, including various cancers and autoimmune disorders. Its work is centered on leveraging advanced T-cell engineering and molecular research to address complex disease mechanisms.

How does Atara Biotherapeutics generate revenue?

The company operates as a single integrated research and development entity, primarily generating revenue through its collaborative partnerships, licensing agreements, and the advancement of its therapeutic candidates through clinical development. Its business model emphasizes innovation and strategic collaborations within the biotech sector.

What types of therapies does Atara Biotherapeutics develop?

The company specializes in developing T-cell based therapies, including those utilizing CAR T platforms, and other cellular-based treatments. Its therapeutic candidates are designed to tackle the underlying biological mechanisms of diseases such as cancers, solid tumors, and autoimmune conditions.

Who are some of Atara Biotherapeutics' key collaborators?

Atara Biotherapeutics collaborates with renowned medical research institutions and cancer centers, enhancing its research and clinical development capabilities. These collaborations facilitate access to specialized expertise, rigorous testing protocols, and shared insights that drive its therapeutic innovation.

How does the company differentiate itself within the competitive biotech industry?

Atara differentiates itself through a focused approach on cellular and T-cell therapies, underpinned by deep scientific research and strategic clinical partnerships. Its commitment to addressing complex disease mechanisms with mechanism-driven therapies sets it apart from more generalized treatment developers.

What is the significance of the company’s research on growth factors?

The research into growth factors such as activin and myostatin is central to Atara’s strategy, as these molecules play a crucial role in disease progression. By targeting these factors, the company aims to modulate the underlying biological processes, offering novel and potentially more effective treatment solutions.

What should investors know about Atara Biotherapeutics' business model?

Investors should note that Atara operates with a singular focus on therapeutic innovation within the biotherapeutics sphere. Its business model is centered on comprehensive R&D, strategic partnerships, and advancing novel therapeutic candidates, which collectively build a foundation of scientific expertise and operational efficiency.
Atara Biotherape

Nasdaq:ATRA

ATRA Rankings

ATRA Stock Data

34.83M
4.56M
21.98%
50.5%
12.2%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
THOUSAND OAKS